CY1121332T1 - Μiμhtiκα καλσιτονινης προς θεραπεια ασθενειων και διαταραχων - Google Patents
Μiμhtiκα καλσιτονινης προς θεραπεια ασθενειων και διαταραχωνInfo
- Publication number
- CY1121332T1 CY1121332T1 CY20191100252T CY191100252T CY1121332T1 CY 1121332 T1 CY1121332 T1 CY 1121332T1 CY 20191100252 T CY20191100252 T CY 20191100252T CY 191100252 T CY191100252 T CY 191100252T CY 1121332 T1 CY1121332 T1 CY 1121332T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- poorly regulated
- seq
- amino acid
- type
- Prior art date
Links
- 208000037765 diseases and disorders Diseases 0.000 title 1
- BBBFJLBPOGFECG-UHFFFAOYSA-N salmon calcitonin Chemical compound C=1N=CNC=1CC(C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(C(C)O)C(=O)NC(CC=1C=CC(O)=CC=1)C(=O)N1C(CCC1)C(=O)NC(CCCNC(N)=N)C(=O)NC(C(C)O)C(=O)NC(CC(N)=O)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CO)C(=O)NCC(=O)NC(C(C)O)C(=O)N1C(CCC1)C(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(C(C)C)NC(=O)C1CSSCC(N)C(=O)NC(CO)C(=O)NC(CC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)N1 BBBFJLBPOGFECG-UHFFFAOYSA-N 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 abstract 3
- 150000001413 amino acids Chemical group 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000055006 Calcitonin Human genes 0.000 abstract 1
- 108060001064 Calcitonin Proteins 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 206010020710 Hyperphagia Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010033307 Overweight Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract 1
- 229960004015 calcitonin Drugs 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 238000007446 glucose tolerance test Methods 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 235000020830 overeating Nutrition 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/585—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Μιμητικά πεπτίδια καλσιτονίνης που έχουν μια αλληλουχία αμινοξέων σύμφωνα με τον ΑΡ. ΤΑΥΤΟΤΗΤΑΣ ΑΛΛΗΛΟΥΧΙΑΣ: 8 ή τον ΑΡ. ΤΑΥΤΟΤΗΤΑΣ ΑΛΛΗΛΟΥΧΙΑΣ: 53, καθένα από τα οποία μπορεί να είναι καρβοξυλιωμένο στο Ν-τερματικό ή τροποποιημένο με άλλο τρόπο για να μειώσει το θετικό φορτίο του πρώτου αμινοξέος. Ανεξάρτητα από αυτό μπορεί να είναι αμιδιωμένα στο C-τερματικό και σε κάθε ένα από τα οποία τα υπολείμματα κυστεΐνης της θέσης 1 και 7 μπορούν να τοποθετηθούν μαζί με ένα α-αμινοσουβερικό οξύ (Asu). Τα εν λόγω πεπτίδια είναι χρήσιμα ως φάρμακα για την θεραπεία του διαβήτη (Τύπου I και / ή Τύπου II), του υπερβολικού σωματικού βάρους, της υπερβολικής κατανάλωσης τροφής, του μεταβολικού συνδρόμου, της ρευματοειδούς αρθρίτιδας, της μη αλκοολικής λιπώδους νόσου του ήπατος, της οστεοπόρωσης ή της οστεοαρθρίτιδας, των κακώς ρυθμισμένων επιπέδων γλυκόζης του αίματος, της ανεπαρκώς ρυθμισμένης απόκρισης σε δοκιμές ανοχής γλυκόζης ή της κακώς ρυθμισμένης πρόσληψης τροφής.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201320112A GB201320112D0 (en) | 2013-11-14 | 2013-11-14 | Calcitonin Mimetics for treating diseases and disorders |
| GB201414706A GB201414706D0 (en) | 2014-08-19 | 2014-08-19 | Calcitonin mimetics for treating diseases and disorders |
| PCT/EP2014/074207 WO2015071229A1 (en) | 2013-11-14 | 2014-11-10 | Calcitonin mimetics for treating diseases and disorders |
| EP14802345.0A EP3068796B1 (en) | 2013-11-14 | 2014-11-10 | Calcitonin mimetics for treating diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121332T1 true CY1121332T1 (el) | 2020-05-29 |
Family
ID=51947308
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100253T CY1119976T1 (el) | 2013-11-14 | 2018-02-28 | Μιμητικα καλσιτονινης για την αντιμετωπιση ασθενειων και διαταραχων |
| CY20191100252T CY1121332T1 (el) | 2013-11-14 | 2019-02-28 | Μiμhtiκα καλσιτονινης προς θεραπεια ασθενειων και διαταραχων |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100253T CY1119976T1 (el) | 2013-11-14 | 2018-02-28 | Μιμητικα καλσιτονινης για την αντιμετωπιση ασθενειων και διαταραχων |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10232021B2 (el) |
| EP (3) | EP3470422A1 (el) |
| JP (1) | JP6639389B2 (el) |
| KR (1) | KR20160075794A (el) |
| CN (1) | CN105722854B (el) |
| AU (2) | AU2014350328B2 (el) |
| BR (1) | BR112016010643A2 (el) |
| CA (1) | CA2928654A1 (el) |
| CY (2) | CY1119976T1 (el) |
| DK (2) | DK3068796T3 (el) |
| ES (2) | ES2713851T3 (el) |
| HR (2) | HRP20180337T1 (el) |
| HU (2) | HUE037663T2 (el) |
| LT (2) | LT3321278T (el) |
| MX (1) | MX2016006049A (el) |
| NO (1) | NO3068796T3 (el) |
| PH (1) | PH12016500705B1 (el) |
| PL (2) | PL3068796T3 (el) |
| PT (2) | PT3321278T (el) |
| RS (2) | RS58530B1 (el) |
| RU (1) | RU2689551C1 (el) |
| SI (2) | SI3068796T1 (el) |
| TR (1) | TR201802765T4 (el) |
| WO (1) | WO2015071229A1 (el) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201500263D0 (en) * | 2015-01-08 | 2015-02-25 | Keybioscience Ag | Calcitonin analogues for treating diseases and disorders |
| KR101869595B1 (ko) | 2016-06-08 | 2018-06-21 | 부경대학교 산학협력단 | 성게 유래 칼시토닌 유사 펩타이드를 유효성분으로 포함하는 골 질환 예방 또는 치료용 조성물 |
| CN108424460A (zh) * | 2017-02-13 | 2018-08-21 | 成都贝爱特生物科技有限公司 | GLP-1类似物和davalintide类似物的融合蛋白制备及其用途 |
| CN106880835A (zh) * | 2017-02-17 | 2017-06-23 | 云南同方科技有限公司 | 用于缓解高血压症状的植物精油复合物制备及应用 |
| GB201704429D0 (en) | 2017-03-21 | 2017-05-03 | Keybioscience Ag | Calcitonin mimetics for treating diseases and disorders |
| GB201707955D0 (en) | 2017-05-18 | 2017-07-05 | Keybioscience Ag | Dual amylin and calcitonin receptor agonists for treating diseases and disorders |
| GB201813678D0 (en) | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Acylated calcitonin mimetics |
| GB201813677D0 (en) | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Calcitonin mimetics for treating diseases and disorders |
| CA3156452A1 (en) | 2019-11-11 | 2021-05-20 | Boehringer Ingelheim International Gmbh | NPY2 RECEPTOR AGONISTS |
| KR20230045088A (ko) | 2020-08-07 | 2023-04-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 가용성 npy2 수용체 작용제 |
| AR124295A1 (es) | 2020-12-18 | 2023-03-15 | Lilly Co Eli | Agonistas duales del receptor de amilina y calcitonina y usos de los mismos |
| WO2024050289A1 (en) | 2022-08-29 | 2024-03-07 | Eli Lilly And Company | Compositions for oral delivery |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319685B1 (en) | 1984-09-27 | 2001-11-20 | Unigene Laboratories, Inc. | Alpha-amidating enzyme compositions and processes for their production and use |
| US4708934A (en) | 1984-09-27 | 1987-11-24 | Unigene Laboratories, Inc. | α-amidation enzyme |
| US5789234A (en) | 1987-08-14 | 1998-08-04 | Unigene Laboratories, Inc. | Expression systems for amidating enzyme |
| JPH03240797A (ja) * | 1990-02-15 | 1991-10-28 | Sagami Chem Res Center | 新規カルシトニン誘導体 |
| US5102666A (en) | 1990-09-11 | 1992-04-07 | Oramed, Inc. | Calcium polycarbophil controlled release composition and method |
| JPH04149198A (ja) * | 1990-10-12 | 1992-05-22 | Sagami Chem Res Center | カルシトニン誘導体 |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US6692766B1 (en) | 1994-06-15 | 2004-02-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Controlled release oral drug delivery system |
| US5866536A (en) | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| US5773647A (en) | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| AU742270B2 (en) | 1997-04-16 | 2001-12-20 | Enteris Biopharma, Inc. | Direct expression of peptides into culture media |
| DE19736457C2 (de) * | 1997-08-21 | 2001-08-23 | Fraunhofer Ges Forschung | Calcitonin-Derivate mit einer Verbrückung zwischen den Aminosäuren an den Positionen 17 und 21 |
| WO2000033866A1 (en) | 1998-12-04 | 2000-06-15 | Provalis Uk Limited | Pharmaceutical compositions containing insulin |
| ATE288415T1 (de) | 1999-04-05 | 2005-02-15 | Emisphere Tech Inc | Dinatrium-salze, monohydrate und ethanol-solvate |
| US6780846B1 (en) | 1999-09-27 | 2004-08-24 | Elan Corporation, Plc | Membrane translocating peptide drug delivery system |
| GB2368792A (en) | 2000-10-06 | 2002-05-15 | Roger Randal Charles New | Absorption enhancers |
| US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
| US7316819B2 (en) | 2001-03-08 | 2008-01-08 | Unigene Laboratories, Inc. | Oral peptide pharmaceutical dosage form and method of production |
| US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| JP2006521366A (ja) | 2003-03-28 | 2006-09-21 | シグモイド・バイオテクノロジーズ・リミテッド | シームレスマイクロカプセルを含む固形経口剤形 |
| GB0308732D0 (en) | 2003-04-15 | 2003-05-21 | Axcess Ltd | Absorption enhancers |
| PL1651249T3 (pl) | 2003-07-23 | 2013-04-30 | Novartis Ag | Zastosowanie kalcytoniny w zapaleniu kości i stawów |
| US20070172517A1 (en) | 2003-09-17 | 2007-07-26 | Ben-Sasson Shmuel A | Compositions capable of facilitation penetration across a biological barrier |
| WO2006008270A1 (de) | 2004-07-22 | 2006-01-26 | Thiomatrix Forschungs- Und Beratungs Gmbh | Verwendung von thiolgruppen-hältigen verbindungen als efflux-pumpen-hemmer |
| US7445911B2 (en) | 2004-11-24 | 2008-11-04 | Unigene Laboratories Inc. | Enzymatic reactions in the presence of keto acids |
| JP4856177B2 (ja) | 2005-06-24 | 2012-01-18 | ユニジーン・ラボラトリーズ・インコーポレーテッド | アミド化生成物の調製に有用な酵素を発現させるための細胞株 |
| JP5222727B2 (ja) | 2005-09-06 | 2013-06-26 | オーラメッド・ファーマスーティカルズ・インコーポレイテッド | タンパク質を経口投与するための方法及び組成物 |
| US8093207B2 (en) | 2005-12-09 | 2012-01-10 | Unigene Laboratories, Inc. | Fast-acting oral peptide pharmaceutical products |
| ES2369244T3 (es) | 2006-03-13 | 2011-11-28 | Advancell Advanced In Vitro Cell Technologies,S.A. | Sistemas estables de nanocápsulas para la administración de moléculas activas. |
| EP2007397B1 (en) | 2006-04-07 | 2013-07-24 | Merrion Research III Limited | Solid oral dosage form containing an enhancer |
| US8377863B2 (en) | 2007-05-29 | 2013-02-19 | Unigene Laboratories Inc. | Peptide pharmaceutical for oral delivery |
| US8962015B2 (en) | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
| EP3515022B1 (en) * | 2011-10-25 | 2022-08-17 | Nicira Inc. | Chassis controllers for converting universal flows |
| AU2012332265B2 (en) * | 2011-11-02 | 2016-11-10 | Keybioscience Ag | Peptide analogs for treating diseases and disorders |
-
2014
- 2014-11-10 PL PL14802345T patent/PL3068796T3/pl unknown
- 2014-11-10 HU HUE14802345A patent/HUE037663T2/hu unknown
- 2014-11-10 SI SI201430612T patent/SI3068796T1/en unknown
- 2014-11-10 LT LTEP17208140.8T patent/LT3321278T/lt unknown
- 2014-11-10 CN CN201480062032.2A patent/CN105722854B/zh not_active Expired - Fee Related
- 2014-11-10 SI SI201431101T patent/SI3321278T1/sl unknown
- 2014-11-10 CA CA2928654A patent/CA2928654A1/en not_active Abandoned
- 2014-11-10 WO PCT/EP2014/074207 patent/WO2015071229A1/en active Application Filing
- 2014-11-10 US US15/036,475 patent/US10232021B2/en not_active Expired - Fee Related
- 2014-11-10 ES ES17208140T patent/ES2713851T3/es active Active
- 2014-11-10 RU RU2016123180A patent/RU2689551C1/ru active
- 2014-11-10 BR BR112016010643A patent/BR112016010643A2/pt active Search and Examination
- 2014-11-10 EP EP18208763.5A patent/EP3470422A1/en not_active Withdrawn
- 2014-11-10 NO NO14802345A patent/NO3068796T3/no unknown
- 2014-11-10 ES ES14802345.0T patent/ES2660788T3/es active Active
- 2014-11-10 PT PT17208140T patent/PT3321278T/pt unknown
- 2014-11-10 AU AU2014350328A patent/AU2014350328B2/en not_active Ceased
- 2014-11-10 HU HUE17208140 patent/HUE044465T2/hu unknown
- 2014-11-10 RS RS20190279A patent/RS58530B1/sr unknown
- 2014-11-10 RS RS20180244A patent/RS57152B1/sr unknown
- 2014-11-10 MX MX2016006049A patent/MX2016006049A/es active IP Right Grant
- 2014-11-10 PT PT148023450T patent/PT3068796T/pt unknown
- 2014-11-10 TR TR2018/02765T patent/TR201802765T4/tr unknown
- 2014-11-10 PL PL17208140T patent/PL3321278T3/pl unknown
- 2014-11-10 EP EP14802345.0A patent/EP3068796B1/en active Active
- 2014-11-10 EP EP17208140.8A patent/EP3321278B1/en active Active
- 2014-11-10 DK DK14802345.0T patent/DK3068796T3/en active
- 2014-11-10 KR KR1020167015410A patent/KR20160075794A/ko active IP Right Grant
- 2014-11-10 DK DK17208140.8T patent/DK3321278T3/en active
- 2014-11-10 LT LTEP14802345.0T patent/LT3068796T/lt unknown
- 2014-11-10 JP JP2016530131A patent/JP6639389B2/ja not_active Expired - Fee Related
-
2016
- 2016-04-15 PH PH12016500705A patent/PH12016500705B1/en unknown
-
2018
- 2018-02-26 HR HRP20180337TT patent/HRP20180337T1/hr unknown
- 2018-02-28 CY CY20181100253T patent/CY1119976T1/el unknown
- 2018-04-09 AU AU2018202480A patent/AU2018202480A1/en not_active Abandoned
-
2019
- 2019-01-21 US US16/252,780 patent/US20190142903A1/en not_active Abandoned
- 2019-02-25 HR HRP20190356TT patent/HRP20190356T1/hr unknown
- 2019-02-28 CY CY20191100252T patent/CY1121332T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121332T1 (el) | Μiμhtiκα καλσιτονινης προς θεραπεια ασθενειων και διαταραχων | |
| CY1121462T1 (el) | Ακυλιωμενα αναλογα γλυκαγονης | |
| CY1122465T1 (el) | Συνδυασμενη φαρμακευτικη συνθεση | |
| CY1123450T1 (el) | Μεθοδος καθαρισμου συζευγματων βασει il-15/il-15ra | |
| CY1120055T1 (el) | Αντικαρκινικη πρωτεϊνη συντηξης | |
| BR112017024797A2 (pt) | neoantígenos partilhados | |
| BR112016013138A2 (pt) | mistura de peptídeos | |
| EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
| EA201000424A1 (ru) | Антитела к il-23 | |
| BR112018001572A2 (pt) | método para induzir uma resposta imune, antígeno, adenovírus, uso de um antígeno e de um adenovírus, e, polinucleotídeo. | |
| PE20211272A1 (es) | POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO | |
| GT201200271A (es) | Proteínas que se unen al tnf-a | |
| CY1116646T1 (el) | Αντικαρκινικη πρωτεϊνη συντηξης | |
| MX2016001555A (es) | Modulocinas basadas en dominio sushi de interleucina-15 (il-15) y receptor alfa de interleucina-15 (il-15ra). | |
| CY1119149T1 (el) | Αντικαρκινικη πρωτεϊνη συντηξης | |
| BR112014029966A2 (pt) | proteínas de fator de crescimento de fibroblasto 21 | |
| BR112016029713A8 (pt) | uso de uma carboximetilcelulose reticulada e uso de um agente gelificante | |
| CL2017003228A1 (es) | Fragmentos mutantes de proteína ras | |
| BR112017014580A8 (pt) | Método para obter um isolado peptídico a partir de uma biomassa de microalgas enriquecidas com proteína | |
| BR112017008525A2 (pt) | proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo. | |
| BR112016011930A2 (pt) | combinações de peptídeos e seus usos em tratamento de alergia de ácaro de poeira | |
| BR112017017609A2 (pt) | proteína de fusão fc, e, composição farmacêutica. | |
| MX2009007572A (es) | Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y. | |
| ES2721159T3 (es) | Antígenos asociados a tumor independientes de MHC novedosos | |
| PH12015502100A1 (en) | Reducing the risk of autoimmune disease |